At the 2025 World Conference on Lung Cancer, multiple studies showcased advances in lung cancer treatment. BioNTech and Bristol Myers Squibb’s bispecific PD-L1/VEGF inhibitor pumitamig demonstrated a 76% tumor shrinkage rate in small cell lung cancer Phase II trials. Meanwhile, Daiichi Sankyo and Merck reported a 48.2% objective response with ifinatamab deruxtecan in extensive-stage small cell lung cancer. Additionally, surgery following EGFR TKI therapy showed progression-free survival benefits in metastatic NSCLC patients; however, Summit Therapeutics' bispecific antibody ivonescimab failed to improve overall survival in a global Phase III trial, underscoring regional differences in efficacy.